INOVIz

Medical Brokerage Event May 25, 2010

<>Turkey (45) <>Austria (1) <>Germany (1) <>Greece (2) <>Isreal (22) <>Italy (4) <>United States (9)

Austria

GR- APUS Software GmbH

Giuseppe Reggia

Full Description

APUS Software GmbH was established in 1987 and has specialized in solving complex customer software requirements. APUS is an experienced ISO 9001:2000 certificated supplier of software solutions and has currently 29 employees. APUS Software GmbH operates the following 2 divisions: + Software Engineering and Simulation software + Resource Planning Software for simulation In the area of simulation software eingineering, we provide on the one hand a broad spectrum of software engineering services regarding complex software systems and applications. LuSI, our software for CARDIORESPIRATORY PATIENT SIMULATION, was designed for pulmonary medicine, enabling young physicians to gain experience. This model was engineered in the context of a pilot project run in coopetion with a local hospital in Austria and proved to be really helpulful for the analysis of difficult respiratory situations, which may occur at any time in patients with limited lung functions. This model consists of a real time ventilator and of a lung model. On the other hand, the resource planning division of APUS Software GmbH develops, operates and maintains GrapDi®,a resource planning, staff rostering and time recording software application with a flexible, script-based configuration of working time directives. It is currently used by most of Austrian's largest health care organizations. We are in search of partner companies interested in our software solutions and in entering a profitable co-operation based on mutual profiling opportunities.

Greece

MEDICAL TECHNOLOGY S.A. (WOLFM

Anastasios Tsiaousidis

Full Description

MEDICAL TECHNOLOGY SA (Wolfmedica Hellas) is a leading manufacturer in design and production of medical equipment and furniture, specialising, for more than a decade, in the cardiology and gynaecology and rehabilitation fields. In all the years of our active presence in the market, we have been known for our creative thinking and solid engineering, values that we try to imbue in all of our products. During that time, we have managed to remain close to our customers and we have convinced them that high quality medical products can be reasonably priced. Our fully automated production line, utilising cutting edge technology in robotic welding, CNC milling and drilling and vacuum thermoforming, has a dynamic monthly output standard of 500 beds and 50 treadmills or 200 beds and 200 treadmills. Being a family owned company, our main concern is customer satisfaction. The Quality Policy is applied to and focused on every product and service that is provided. Quality control, following the European Standards, is applied to all stages of production and concerns all people involved. Our management team is committed in delivering top quality products and services by implementing quality policies and setting goals. This commitment is shared by all employees at all levels of production, in order to maximise customer satisfaction. We are looking for partners in distribution and subcontracting fields

Isreal

Israel EEN.1

shmuel zissman

Full Description

An Israeli manufacturer, world-leader supplier of OEMs (Original Equipments Manufacturers) in the field of high-precision laser cutting & welding and micro-machining, providing totally comprehensive engineering and manufacturing platforms to the medical devices, bioengineering and hi-tech industries, seeks design and new products in the field of medical devices, mainly in the bio-engineering and stent area. • Processing miniature metal parts, using cutting-edge measurement tools. • Micro-machining -processed by laser equipment. • Laser welding of mixed materials. • Micro laser welding - specialised in laser cutting and welding of miniature metal parts.

Isreal

Israel EEN.2

Shmuel Zissman

Full Description

The sleep-related breathing disorders are known to result in heart diseases, car accidents, heart attacks, high blood-pressure, stroke and other cardiovascular disorders. The company specializing in precise measurements has developed a biofeedback system, which includes a built-in non-intrusive home sleep lab. The system senses passively the vital signs from beneath the mattress, monitors sleep behavior and outputs a gentle biofeedback upon snore detection to stop snores and other respiration disorders. This is the way the system allows a user to enjoy free air flow to reduce or cease snoring and other related respiration disorders. The system improves sleep quality and can bring to a reduction of the risk of longterm heart-related conditions. The system uses sensing of vital signs and the analyses of lungs, air passages etc. and allows the same sensor to detect the heart and respiration activity. The system is intended for manufacturing / distributing companies in the field of health-care industrial applications. The end-users may be both hospitals and private users.

Isreal

Israel EEN.3

shmuel zissman

Full Description

The identification of specific cell markers and characteristics of stem cells has been only partially successful thus far. Several specific cell molecules are currently in use for stem cell isolation, but there is no agreement on unique markers and “stemness signatures”. For example, bone marrow transplants have succeeded using stem cells selected by “specific markers” which function is poorly characterized and none are distinctive. The SME developed an alternative way to select stem cells: selection by function. Cell death (apoptosis) plays a pivotal role in the regulation of cell growth in the fetus and adult. The resistance to death is an intrinsic mechanism in a variety of stem cells and disappears upon differentiation and proliferation. Through intensive laboratory work, the SME formulated a procedure that exploits this resistant characteristic of stem cells so that they survive treatment while other cells undergo apoptosis. The procedure involves binding of cell surface receptors that normally signal cell death in differentiating and proliferating cells, thereby providing the means for isolation of stem cells from non-stem cells. Since stemness is basically a state in which some cells can get into and out from, using the functional characteristics of a stem cells makes much more sense when trying to isolate these populations.

Isreal

Israel EEN.4

shmuel zissman

Full Description

An Israeli SME develops and produces a comprehensive line of unique and innovative healthcare textile wear and accessories for hospitals,nursing homes and their personnel. The SME line of products can mainly be described as being impenetrable for any medical contamination, antistatic and sustainable through almost 75 washing cycles. The SME employs in its daily operation the leading-edge technology which enables them implementing innovation in their day-to-day business challenges. The following is a summary of the SME products in the line of healthcare and medical products, including a short description over their uniqueness and innovation: HEALTHCARE APPAREL - Highest quality healthcare apparel available to the market made from a wide variety of styles, colors, and sizes. SHEETS & PILLOWCASES - Using state-of-the art air jet weaving machines the SME manufactures the widest variety of single-pick woven sheeting products available from any source. TERRY PRODUCTS - Whether through innovations such as the SME Centium® Core Technology or the cost-saving convenience of the SME proprietary pre washing process, the SME delivers cost-effective, ready-for-use terry products unlike any other available product. The SME is a vertically integrated company that manages its own extensive research and development operations, manufacturing and distribution. The SME is committed to total cost solutions by providing innovative linen management consulting, clinical engineering and technical expertise. Service, quality, innovation & cost effectiveness are areas in which the SME excels,through the combination of product design and development, process innovation and cost controls in the manufacturing and in the supply chain operations. The SME is recognised as the global leader in the manufacturing of healthcare and surgical textile, supplying worldwide quality assured products at the most possible competitive prices.

Isreal

Israel EEN.5

shmuel Zissman

Full Description

Integrated regional system of physician application is a place where the physician does his documentation duty. Hence, health care organizations can use the system as a strategic asset for managing costs, expenses & delivering better health services. The company offers the concept, which treats EMR as the ERP (Enterprise Resource Planning System) of the organization, or "medical production floor". The EMR is a Windows-based proprietary technology, provides for client/server application. It is an Integrated Electronic Medical Record (EMR) System, Regional or National, which acts as the desktop of a physician. The offered system provides an HMO (health management organization) for a) controlling all enterprise-wide information, b) implementing organizational strategies, c) increasing physician efficiency, d) high quality of health care, e) cost controls, f) preventive medicine analysis (PMA), g) outcome management, h) fraud elimination. The offered system enables the physician to a) save time (as patient data are built from various sources), b) communicate with central and peripheral systems, c) clinical decision support tools and preventive medicine guidelines, d) extensive graphic utilities (lab results, vital signs,

Isreal

Israel EEN.6

Shmuel Zissman

Full Description

The solution offered is designed to provide a comprehensive solution for controlling remote inventory items for the Health care industry and increase the availability of critical items while enabling the user to control all relevant aspects via the Internet. The system automatically monitors inventory levels, inventory out of stock, and inventory with expired date. The smart solution is seamlessly controlled by advance web based software, which provides on line real time view of the remote inventory. Innovative sophisticated statistics algorithms are used to recommend inventory level and automatically record the consumed items and associate theremoval or replacement of each item with a particular deployment and work order/patient.

Isreal

Yissum Tech.1

Ariel Darvasi

Full Description

Access to DNA samples from 16 common diseases: Type I diabetes, type II diabetes, asthma, colorectal cancer, breast cancer, prostate cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, migraine, hypertension, coronary artery disease, schizophrenia, bipolar disorder, schizoaffective disorder, and rheumatoid arthritis. More than 500 samples per disease for most diseases and a common panel of 6000 healthy controls. Customers may request to genotype any number of SNPs on any number of samples (cases and controls). Genotyping is performed in a central laboratory and included within the service (DNA is not shipped to customers)

Isreal

Yissum Tech.12

Gershon Golomb

Full Description

The laboratory is active in the field of advanced drug delivery systems and formulations of biological active agents. We have expertise in the development and evaluation of controlled release drug delivery systems, targeted delivery, nanoparticles, liposomes and implantable devices, and in general formulations of pharmaceuticals Research provided * Formulations of drugs, peptides, proteins and genes (pDNA, antisense siRNA) in advanced dosage forms Advantages * The laboratory is staffed with highly knowledgeable, skilled researchers using state-of-the-art technologies and equipment * Capacity for development and evaluation in animal models Client record * Numerous leading pharmaceutical companies Certification * Radioactive certified lab * SPF animal facilities

Isreal

Yissum Tech.13

Elena Canetti

Full Description

OBCEJTIVE /FUNCTION Research tools for disease investigation comprising n in vivo mouse model systems that mimic the immunosuppressive environment generated in individuals with chronic inflammatory diseases and ex vivo models based on the in vivo model that retain the chronic‐inflammation induced immunosuppressive conditions. Service Provided • The model systems are research tools for the investigation of cancer, chronic infections and autoimmune diseases. In these pathologies, chronic inflammation develops leading to immunosuppression associated with a decreased expression of a specific T cell biomarker. This phenomenon is reversible upon recovery from the chronic inflammation. • Platform for testing neutralizing agents for their capacity to restore the expression of the T cell biomarker and enhanced immune competence. • The T cell biomarker expression may be used as a diagnostic/prognostic tool to detect chronic inflammation‐induced immunosuppressive environment. Advantages • The mice in these models do not suffer from any pathology that interferes with their normal physiology. • Results obtained from these systems reflect the interrelationships between the innate and adaptive immune systems under chronic inflammatory conditions, which are relevant to a wide range of inflammatory diseases. • The model systems can be used as platforms for: * Testing reagents such as anti‐inflammatory drugs and small molecules for their capacity to neutralize the inflammatory/immunosuppressive environment, restoring changes in the cell biomarker and gain immune competence * Identifying immunosuppressive compounds * Identifying T cell molecules involved in the induced immunosuppression * Testing expression levels of the T cell biomarker for detecting the appearance of an immunosuppressive environment in tumor‐bearing hosts and predicting immunotherapy timing and success

Isreal

Yissum Tech.14

Mottie Chevion

Full Description

Objective/function The Chevion Heart Research Laboratory is associated with the Dr. Ganz Chair of Heart Studies and conducts scientific activities related to protecting the ischemic heart by various methodologies,including the use of anti‐oxidative agents, specific drugs and types of pre‐conditioning. Service Provided • New and classical methodologies are employed to evaluate the capacity of the heart to withstand severe ischemia and subsequent reperfusion. Recently, several approved drugs in clinical use, including anti‐diabetic and anti‐inflammatory drugs, have been found to cause injury to the heart and their use halted. The Chevion Heart Research Laboratory employs novel methodologies to provide an a priori evaluation of whether a drug will cause heart damage, and possibly identify the mechanism through which the injury takes place. • Similar methodologies can be adapted to the evaluation of the effects of such drugs on the kidney and/or liver. Advantages: • The Laboratoryʹs technologies may be used to evaluate possible deleterious effects of new drugs on the heart, similar to the mandatory requirement for complete toxicological evaluations of new drugs, prior to public use. This would prevent the need to ban a drug after it has been approved and is in clinical use, avoiding damage to the drug companyʹs reputation and saving funds. Available Resources The Chevion Heart Research Laboratory is equipped with two advanced systems for running experiments utilising isolated heart models coupled to a PC‐based data acquisition and manipulation system, as well as all necessary equipment for physiological and biochemical measurements. In addition, the Laboratory enjoys free access to additional general and heavy equipment of the Department of Inter‐Departmental Equipment located in the same building.

Isreal

Yissum Tech.15

Amiram Goldblum

Full Description

Research Capabilities • Developing and applying novel optimization algorithms for the design and discovery of novel therapeutics, from small molecules and peptidomimetics to peptides and proteins. • Ability to produce focused libraries of potentially highly active ligands for specific targets in a matter of days • Collaborating with researchers on treating diseases such as cancer, Alzheimer's and others • Solving complex problems in structural biology: protein-ligand interactions and docking, protein-protein recognition, predicting unstructured proteins Advantages The lab's proprietary core technology, called Iterative Stochastic Elimination (ISE), is used to find optimal solutions to diverse issues such as sets of best ligands for a target, molecular conformational ensembles and properties, multiple loops in proteins, protein-ligand docking, protein design, focused libraries, chemoinformatics and others. ISE finds global and local minima and produces very large sets of optimal solutions from which to choose based on needs and requirements. Research Background The laboratory has expertise in a broad field of life sciences ranging from physics and chemistry to biology and structural biology, and includes computer science experts. Researcher and Research Interests Professor Amiram Goldblum, Institute for Drug Research, School of Pharmacy. Professor Goldblum's optimization algorithm received the first prize of the American Chemical Society's Computational Chemistry Division in 2000. Since then, it has raised interest for use in many other fields including electronic circuits and investment portfolios. Professor Goldblum's main interests lie in the properties of molecules, intermolecular interactions and catalysis. For many years he used a quantum mechanical approach to his studies whereas recently his focus has been on molecular mechanics solutions.

Isreal

Yissum Tech.16

Yinon Ben Neriah

Full Description

Research Capabilities * Studying signal transduction pathways incorporating phosphorylation and ubiquitination, in particular the NF-κB and Wnt signaling pathways * Understanding the regulation of phosphorylation and the destruction machineries of β-catenin, IκB, key regulators of the Wnt and the NF-κB pathways * Identifying Wnt signaling molecules and their mechanisms of action * Studying the biological consequences of mutations in these pathways in specific animal models with relevance to human disease, particularly cancer, inflammation and immunity Advantages The laboratory, working in close collaboration with Dr. Eli Pikarsky's group, develops proprietary specific animal models for studying the interrelation between the immune system and cancer development. Research Background Research carried out in Professor Ben-Neriah's lab is focused on unravelling the connections between the immune response mechanism and cancer development in order to develop neutralizing reagents that intervene with the immune system and block its support for cancer development.

Turkey

Bioskopi Medical & Pharmaceuti

Orhan Eren

Full Description

Description: Biopsy is a medical test involving the removal of cells or tissues for examination. A Turkish company developed a novel biopsy method that will bring several advantages to patient, save time and money at hospitals. The company needs assistance in development of "needle with atravmatic hole" and "pencil point needle with one hole" to produce necessary equipment for E-cut biopsy. Technical Specifications / Specific technical requirements of the request Standart needle with one hole on top side: 22 gauge XXTW x 40mm with hole length of 1.0mm 23 gauge XXTW x 50mm with hole length of 0.8mm Top is the lancet type. The hole will be on top. The hole will be atravmatic like sprotte cannula Pencil point neddle with one hole: 19 gauge XXTW x 100 mm with hole length of 5mm

Turkey

DEKIM CHEMICALS & PHARMACEUT -

Anil DINCSOY

Full Description

We can provide reliable assistantship in pharmaceutical and medical licensing process ; we can supply accurate demand projections and provide market data for the last 10 years in the national pharmaceutical market. Our company has a large market share in the pharmaceutical tender market and has extensive access to the complete market with efficient inbound and outbound logistics functions. We can provide solid value added services for medical and pharmaceutical producers and license holders abroad who plan to enter the Turkish Market and extend operations in Middle East. Therefore we are willing to initiate commercial contact with parties of parallel interests

Turkey

DEKIM CHEMICALS & PHARMACEUT-2

Anil Dincsoy

Full Description

Scope of Project : 1. Establishment of min 3 max 5 Distribution Centers in Turkey specialized in Pharmaceutical and Medical Products with extensive Cold Chain Storage facilities, designed to operate and provide standard storage services and value added services like printing, packaging etc within Cold Chain Environment and under Good Storage Process standards. 2. Establishment of Cold Chain Multimodal Transport lines between the Distribution Centers with heat monitored transports and multimodal third party logistic options under the standards of Good Distribution Process. 3. Establishment of Cold Chain Multimodal Transport lines between the Distribution Centers and the Recipients with heat monitored transports and multimodal third party logistic options under the standards of Good Distribution Process. We would like to initiate contact with parties who are open to cold-chain logistics projects and/or capital partnerships in such projects and/or can create any form of value-added input in terms of know-how, technology or finance

Turkey

Department of Nuclear Applicat

Perihan Unak

Full Description

RADIOIODINE, RADIOIODINE LABELED URACIL AND URACIL GLUCURONIDE CONJUGATED MAGNETIC NANOPARTICLES Perihan Ünak, Serhan Sakarya, E.İlker Medine Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Bornova, 35100 Izmir, Turkey ADUBILTEM Science and Technology Research and Development Center, Adnan Menderes University, 09100 Aydın, Turkey In so many diseases, drugs which have specifications such as magnetic effect can be directed to the desired site. Thus therapeutic effectiveness of the drugs can be enhanced and side effects can be decreased. The invention involves glucuronide ligand conjugation to magnetic based nanoparticles and then labeling with I-125 and I-131, separately SEM analyses showed that the particles size are 40-60 nm intervals. Labeling yields are found to be 89.4% for I-131 labeled uracil-o-glucuronid conjugated silanated magnetic particles, 92.6% for I-131 labeled uracil-n-glucuronid conjugated silanated magnetic particles. While cellular incorporations for n and o-glucuronides are high comparing to uracil, incorporations for urasil, n and o-glucuronide conjugated magnetic particles are always high. Cellular incorporations for ligand conjugated magnetic particles are much higher under magnetic field.

Turkey

GENMAR

ARDA SAYIK

Full Description

Genmar Diagnostic Company, with its young, dinamic and improver members, gives service on research and diagnostic area approximately for 10 years. In addition to our wide product profile on molecular biology and genetic, we continue to create new openings and to improve our aplication experience that we have through sharing with our customers. Growing technology, following aspects and adding new products to Turkish market without concession is the aim of our company. Through this aim, we make strong relationships with our company distributers that we gained and we will keep our quality on product and technical base by this way. On importance of customer complacence; keeping quality of our products, our service supplied before and after sale, carry our family structure of our company to customers. On this structure, both our customers and company members are always in correlation and sharing and results are all good. Those successes are supported by both seminars, congresses and educations on abroad. We are happy to be your research partner. We continue to improve this sharing and on this phenomena we go emphatically.

Turkey

LABOR İLDAM

ebru hatiper

Full Description

SANYO BIO-MEDİKAL/JAPONYA DNA Amplifikatörü • Kuru Hava Sterilizatörü • Otoklav • Derin Dondurucular (-30,-40,-86,-135, -152ºC) Kit Saklama Dolabı • İnkübatörler( CO2 , Çok gazlı) • Etüv • Soğutmalı İnkübatörler • Yüksek ısı fırınları • Kan saklama dolapları • Bitki geliştirme dolabı • İlaç test dolapları • Temiz ortam yaratn cihazlar • Sıvı nitrojen tankları • Izotermal sıvı nitrojen saklama sistemi SHIMADZU/JAPONYA • Analitik Teraziler • Üstten yüklemeli teraziler• Nem terazisi ve tüm terazi serisi SHERWOOD/İNGİLTERE KLOR ANALİZÖRÜ // SPEKTROFOTOMETRE // MAGNETİK SUSKEPTİBİLİTE TERAZİSİ // MİKRO-KAYNAK CİHAZI // FLUID BED DRYERS // ALEV FOTOMETERESİ LANCER/FRANSA

Turkey

MENE RESEARCH

Arda Karaduman

Full Description

MENE Research is established in 2003 and located in Science-park of Gebze Organized Industrial Zone (GOSB), which is recognized as one of the most developed and modern organized industrial zone in Turkey and planned to be a new company relying on the proven skills of its founder and her colleagues to take the advantage of the growing potential of clinical research activities. Our mission, is to deliver best value to the benefit of patients, clients, employees and government through innovation, trust, speed, quality, global orientation, sound business management and dedication to excellent service. Our vision, is to primarily provide clinical monitoring and supporting services and to design, develop and market new patented software products in the clinical research field.

Turkey

MIH Teknoloji

Ali Murat Akgedik

Full Description

We are manufacturing and also developing medical gastroenterology and urology disposable products .We started manufacturing process in 1999 in Ankara Türkiye. We have been developing three medical products for receiving patented. You will find the our products on the our web page: www.mih.com.tr. Now we are marketing and selling in whole Turkey also Russia, Sudan , Egypt, Georgia , Azerbaijan ,Algeria. Our aim is the best quality, best service to the health industry. At this time, we have been several product projects.And know we are searching financial partners to concluded our projects.

Turkey

Seta Medical Instruments Imp.

Zeynep Dagli

Full Description

Seta Medical is a manufacturing company of medical disposables, operating as a pioneer in the market since 1992. It is one of its kind in Turkey with a totally integrated operation schedule, granted with ISO and CE (CE 0473) certification. The product range consists of disposable gowns, drapes, plastic components and, as a market leader again, custom procedure packs, for which the global demand has increased. Company has totally integrated its production via extrusion, assembling and packaging of the as well its own ETO sterilization process. Also SETA and DuPont have entered into a License Agreement for the DuPont brands of medical fabrics – DuPont™ Softesse®, DuPont™ Suprel® and DuPont™ Acturel®. Via distinctive product labels on gowns and drapes, this agreement permits the visibility in the marketplace of the technology excellence of medical fabrics from DuPont combined with the manufacturing expertise of SETA.

Turkey

Setpa Tıbbi Gereçler İth. İhr.

Oktay Safak

Full Description

We are seeking manufacturing partnership, licensing and/or distribution opportunities on innovative new products. By means of our unique and unmatched approach, we are able to provide near-complete nation-wide tender coverage for any product, either directly by our own group of companies or indirectly through our highly dedicated and experienced network of local distributor companies. Relying on our proven system, we are able to assert that we can make sure your products get the maximum possible market exposure, which enables us to provide you with a constant flow of market info and end-user feedback about your products, as well as high sales figures. We are eager to find opportunities for using our experience in medical products in manufacturing also, preferably on innovative and disruptive new products. We are open to discuss collaboration opportunities with companies and/or individuals seeking a reliable and promising partner in Turkey.

Turkey

Ten Medikal ltd.şti.

Ozan Karadayi

Full Description

Medikal Proje is a project team of experienced engineers and scientists with 20 years of investing experience in the medical field. Medikal Proje promises economic and true solutions in medicine, research & development, food and sterile area related investments. Medikal Proje supports the investor on the investment, provides feasibility. If necessary we provide full support and work with you very closely from the start to the end of your project. Providing help with site selection and full time controlling. Our primary target is to make the investor feel safe about all the steps of the project. To achieve our target, Medikal Proje team continuously screens the investor’s needs, plans and financial support. We work together with the experienced Heysterum-Holland firm to provide a more successful investment Medikal Proje team consists of 20 year experienced members who are trained in investing projects. Our 12 person team includes; industrial engineer, interior architect, Biochemist, Chemical Engineer, Doctor, Economist, Construction engineer, ecological and environmental engineer, metallurgy engineer and technicians. Our team is supported by the internationally experienced Heysterum firm whose headquarter is located in Luxemburg, Holland and also has a branch in Indonesia.

United States

Drexel University

Davood Tashayyod

Full Description

PORTFOILIO OF TECHNOLOGIES AVAILABLE FOR LICENSING
(Please make all appointment with Mr. Davood Tashayyod)

Small Lumin Anastamosis Device (M. Wheatley, A. Brooks, and B. Layton)
VEUSim: A Virtual Endovaginal Ultrasound Simulator for Physician Training: Year II (T. Doehring and N. Handly)
Optical Diagnosis and Treatment Optimization in Chronic Diabetic Wounds: A Pilot Clinical Study – Phase II (E. Papazoglou, K. Pourrezaei, L. Zubkov, and M. Weingarten)
LCL Grafts: Innovative Small Caliber Vascular Grafts for Coronary Bypass Operations (P. Lelkes, R. Levy, and R. Composto)
Real-time Seizure Detection and Control System using Our Patented Ceramic-base Multisite Electrode (K. Moxon and S. Jenssen)
QLISA for Point of Care Detection of Inflammation (E. Papazoglou, S. Murthy, and J. Reynolds)
A Wireless Embedded Intracranial Pressure Monitoring Device – Implantable at Bedside (A. Rosen, and F. Kralick)
Portable Breast Elasticity and Mobility Measurement for Tumor Location and Malignancy Screening (W.Y. Shih, A. Brooks, and W.H. Shih)
Functional Near-infrared Spectroscopy as a Monitor for Depth of Anesthesia (K. Pourrezaei, J. Horrow, and S. Bunce)
Treatment of Lower Back Pain Utilizing a Biomimetic Aggrecan Injection (K. Barbee, M. Marcolongo, E. Vresilovic, and B. Schauer)
Bioactive Alimentary Protein-Based Scaffolds (APS) for Wound Healing and Regenerative Medicine (P. Lelkes, E. Papazoglou, and M. Weingarten)
A Urine Screening Test for Liver Cancer (Y. Su and W. Shih)
Fast Plasma-assisted Hand Disinfection or Sterilization System (G. Fridman, R. Hamilton, S. Joshi, and M. Ingermann)
Syk Kinase as a Biomarker of Skin UV Damage and Photocarcinogenesis (E. Papazoglou and J. Uitto)

United States

Drexel University1

Alexey Melishchuk

Full Description

The QLISA technology is a new in vitro diagnostic test for highly sensitive detection of inflammatory biomarkers and differentiation of IBD vs. IBS. QLISA uses quantum dots to measure inflammatory biomarkers and proprietary surface modifications to provide a superior alternative to the ELISA technique by requiring much smaller sample volumes and simpler assay protocol while preserving ELISA’s sensitivity. The platform is applicable to a 96 well plate format or flat slides of your material of choice. These unique features translate into significant practical advantages of using QLISA as a platform for in vitro diagnostics applications. The initial application of QLISA being developed at Drexel is a diagnostic test discriminating between IBS (irritable bowel syndrome) and IBD (irritable bowel disease). As many as 4 million people worldwide (1 million Americans) suffer from a form of IBD and more than 15 million have IBS, with estimated medical costs in the USA at over $2 billion/yr when adjusted for loss of productivity. IBD refers to two chronic diseases of intestinal inflammation: ulcerative colitis and Crohn's disease. Diagnosing these diseases is an expensive and lengthy process requiring knowledge of medical history, blood tests, X-rays, endoscopy, tissue histopathology and testing of stool samples. As a result, early differentiation of IBS vs. IBD is difficult, which leads to unnecessary excessive testing of IBS patients and significant delays in much needed treatment of IBD patients. Thus, there is a critical need to develop a rapid, low cost, reliable diagnostic test to differentiate common intestinal symptoms of IBS from IBD, to monitor remission and relapses of IBD, and to evaluate success of or need to change medication. The QLISA technology circumvents issues related to sampling and is envisioned for use in a clinical lab environment as a platform for a broad variety of in vitro diagnostic (IVD) tests, including IBD vs. IBS. It can also be used as a research tool in animal experiments and forensic setting where sample size is small. The QLISA Technology is available for licensing from Drexel University. See Paragraph 8 for contact information.

United States

Drexel University2

Alexey Melishchuk

Full Description

The proposed product is a medical device for evaluation of the depth of anesthesia awareness during surgery. The device is based on functional near-infrared (fNIR) technology and relies on optical techniques derived from the physical principles of light absorption and reflectance to detect changes in the hemodynamic response of the cortex to brain activation. A monitoring apparatus for objectively and continuously quantifying the depth of anesthesia of a patient during surgery would not only reduce the incidence of patient awareness (0.13%), but also would allow the anesthesiologist to administer the minimal dose of anesthetic required to achieve the desired depth of anesthesia. The proposed system is intended to be utilized in any settings where sedation is given. As many as 95 million patients annually in the United States undergo procedures for which anesthesia depth monitoring would prove useful, thus affording a potentially large market. The fNIR Depth of Anesthesia Monitoring Technology is available for licensing from Drexel University now.

United States

Drexel University3

Gregory Fridman

Full Description

We will develop a system which will reduce the time required for hand washing from 30 to 60 seconds currently required down to a few seconds thus saving significant portion of time for doctors, nurses, and other hospital personnel. The system will use disinfectant aerosol treated with cold plasma to evenly coat the subject’s hands. The resulting product will be a box where a subject will insert their hands; the box will turn on automatically for a few seconds and turn off with an audible and visual alert that hands are now disinfected and can be removed. The system will be designed to work with all standard disinfectants.

United States

Drexel University4

Alexey Melishchuk

Full Description

Wound Clinics who see patients with challenging wounds need faster evaluation of the healing process to save costs, improve patient outcomes and to be able to transfer some of the wound care to less specialized environments. Yearly incidence of skin ulcers (pressure, venous and diabetic) in the U.S. is estimated to be 6 million patients, and the annual costs for management of these wounds are greater than $20 billion. The current paradigm is measurement of wound size, by tracing or by digital imaging. This superficial evaluation delays proper treatment and results in continuation of non-efficacious products/methods which ultimately lead to amputations. The proposed device uses NIR technology to measure the level of oxygenated and deoxygenated hemoglobin at the wound site and compares it to a control/non-wound site. The time course of the oxygenated hemoglobin was found to be a strong indicator of wound healing. One PCT patent application and one provisional patent application to be converted into a PCT this November protect the method and the system design architecture. We estimate that shortening by 50% the observation time based on wound size,the cost of care for chronic wounds would be reduced by 30-60%. Third-party payers are reimbursing chronic wound care. The business plan of this project just won the 2008-2009 Wharton Business Plan Competition. The Wallace H. Coulter Foundation has invested $200,000 in the research effort during 2006 and 2007 through a competitive proposal process and University City Science Center invested $100,000 in 2009 through its QED program. The Technology is available for licensing from Drexel University. See Paragraph 8 for contact information.

United States

Drexel University5

Alexey Melishchuk

Full Description

Scientists have recently discovered that by delivering electrical stimulation to specific regions of the brain (epileptic focus), they are able to prevent the occurrence of seizures. This technique, also known as neuromodulation, is currently used in open-loop systems where uncontrolled electrical currents are delivered to the nervous system constantly. Due to fear of adverse effects, scientists have begun to focus their efforts on developing a more sophisticated closed-loop system that predicts the occurrence of seizures and delivers the stimulation only when necessary. Current methods of closed-loop neuromodulation are developed based on prediction using EEG recordings,which is difficult and have so far only proven to be 50% effective in predicting seizures. In comparison, we aim to develop an implantable closed-loop neuromodulation device that uses single-neuron recordings to predict seizures. Single-neuron recording is a cutting edge technology in neurological signal recordings. Our Ceramic Based Multi-Site Electrode, developed by Dr. Karen Anne Moxon, Professor of Biomedical Engineering, Neurobiology and Anatomy at Drexel University, allows us to record accurately and chronically from multiple single-neurons in the brain, a feat which has so far been unattainable. This breakthrough in material science and neurological recording allows us to develop an Epilepsy Control System, an implantable device the size of a quarter that can be chronically implanted into an epilepsy patient’s neural tissues using current available surgical methods.

United States

Drexel University6

Alexey Melishchuk

Full Description

The objective of this project is to develop a new staple for small lumen structures fabricated from an FDA approved biocompatible, biodegradable polymer that delivers bioactive agents at a pre-programmed rate to improve healing. The Drug Delivery Surgical Staple is a rapid and efficient anastomotic platform comprised of a staple, shaped like a push clip, which would be sutured by the head to the bile duct. Then, the tail of the staple would be fed into an incision in the small intestine where it would mate with the washer to connect the two tissues together. The staple was designed with threads on its outer diameter in order to lock it with the washer. This way, the staple could snap into the washer and allow for some variation in tightness between the tissues. After time, the staple and washer would slowly degrade in the body as the tissues heal, with the washer releasing wound healing agents, chemotherapeutic agents and/or radioactive therapy thereby assuring delivery of treatment to the site where it is needed most, the surgical margin.

United States

Drexel University7

Alexey Melishchuk

Full Description

Ultrasound examination via natural orifices, such as transesophageal ultrasound for echo cardiography and endovaginal ultrasound for diagnosing gynecologic disorders, are gaining increasing popularity. However,training physicians and medical students to perform these procedures is difficult and expensive due to the complex anatomy of the orifices, shortage of volunteer subjects, and very limited capabilities of available but expensive human mannequin-based systems. To fill this gap in the medical education market Drexel’s clinicians and engineers have developed VEUSim, a virtual reality training system with haptic interface to provide real-life experience of ultrasound examination via a natural orifice. VEUSim has unlimited capabilities for modeling various anatomical structures and creating and modifying associated pathologies, and a unique trainee/instructor interface for recording and quantitative evaluation of trainees’ performance and progress. VEUSim has been developed as a Virtual Endovaginal Ultrasound Simulator (hence the name, VEUSim) as described below, and can be easily adapted to simulate ultrasound examination via any other natural orifice such as esophagus, colon etc. In future this same technology can potentially be utilized for training other Ultrasound, surgery and tracheotomy techniques.

userlogin

Medical Brokerage Event May 25, 2010